22.75
08-10月-24 12:22:10
15 分の遅延
株式
-1.45
-5.99%
本日の幅
22.48 - 26.15
ISIN
N/A
ソース
NASDAQ
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
30 9 2024 08:00:00 提供 Nasdaq GlobeNewswire
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
16 9 2024 16:05:00 提供 Nasdaq GlobeNewswire